Tg Therapeutics (TGTX) Total Liabilities (2010 - 2026)

Tg Therapeutics' Total Liabilities history runs 17 years deep, the most recent figure standing at $945.7 million for Q1 2026.

• In Q1 2026, Total Liabilities rose 125.49% year-over-year to $945.7 million; the TTM figure through Mar 2026 stood at $945.7 million (up 125.49% YoY), while the FY2025 annual figure was $415.2 million, up 16.86% from the prior year.
• Total Liabilities for Q1 2026 stood at $945.7 million, up from $415.2 million in the prior quarter.
• The five-year high for Total Liabilities was $945.7 million in Q1 2026, with the low at $117.4 million in Q3 2022.
• The 5-year median for Total Liabilities is $213.2 million (2024), against an average of $294.3 million.
• The sharpest annual moves came in 2022 and 2024: Total Liabilities dropped 5.26% in 2022, then surged 136.84% in 2024.
• Tg Therapeutics' Total Liabilities stood at $135.0 million in 2022, then climbed by 25.26% to $169.1 million in 2023, then jumped by 110.15% to $355.3 million in 2024, then rose by 16.86% to $415.2 million in 2025, then soared by 127.75% to $945.7 million in 2026.
• Business Quant data shows TGTX's Total Liabilities at $945.7 million in Q1 2026, $415.2 million in Q4 2025, and $417.8 million in Q3 2025.